Payment overview · 2025
General Payments
$6,278.28
85 reported records · 23 companies
Healthcare provider profile · identity verified
Jose Remo, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SULLIVAN, MO · NPI 1598876450
Verified facts
What the public records show
CMS Open Payments records show Jose Remo, MD received $6,278.28 in general payments during 2025 across 85 reported records.
Lilly USA, LLC accounted for 68.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Gemtesa, Jardiance, Mounjaro, Ozempic, Prolia, Qulipta, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $4,292.78 | 68.4% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $563.55 | 9.0% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $402.86 | 6.4% | 23 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $376.24 | 6.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $71.00 | 1.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.48 | 1.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.53 | 1.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.60 | 0.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.33 | 0.7% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $40.49 | 0.6% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.55 | 0.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.06 | 0.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.35 | 0.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.89 | 0.5% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $20.94 | 0.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.54 | 0.3% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.39 | 0.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.99 | 0.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.33 | 0.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.81 | 0.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.72 | 0.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.14 | 0.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.71 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $3,750.00 | 3 |
| Food and Beverage | $2,136.28 | 81 |
| Travel and Lodging | $392.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $1,225.78 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $498.46 | 14 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $376.24 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $222.38 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $188.96 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $114.30 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $106.11 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $71.00 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $51.60 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.17 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $40.49 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $39.55 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.06 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.86 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.86 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.67 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $34.67 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $34.62 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.89 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.33 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.25 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 44 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 277 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 155 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 27 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 153 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
213 | 45 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
277 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
44 | 44 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
27 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
153 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
277 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
108 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
155 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
319 | 53 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1421 | 294 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1095 | 202 |
| Amlodipine Besylate | Amlodipine Besylate | 860 | 180 |
| Lisinopril | Lisinopril | 707 | 157 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 647 | 125 |
| Gabapentin | Gabapentin | 624 | 112 |
| Omeprazole | Omeprazole | 509 | 108 |
| Tramadol Hcl | Tramadol Hcl | 505 | 115 |
| Furosemide | Furosemide | 503 | 108 |
| Metformin Hcl | Metformin Hcl | 500 | 104 |
| Losartan Potassium | Losartan Potassium | 472 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 465 | 84 |
| Potassium Chloride | Potassium Chloride | 457 | 92 |
| Trazodone Hcl | Trazodone Hcl | 454 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 399 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 383 | 101 |
| Alprazolam | Alprazolam | 377 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 372 | 73 |
| Irbesartan | Irbesartan | 355 | 70 |
| Meloxicam | Meloxicam | 335 | 76 |
| Citalopram Hbr | Citalopram Hydrobromide | 319 | 59 |
| Eliquis | Apixaban | 319 | 53 |
| Carvedilol | Carvedilol | 315 | 58 |
| Baclofen | Baclofen | 304 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 290 | 46 |
| Spironolactone | Spironolactone | 280 | 63 |
| Jardiance | Empagliflozin | 277 | 50 |
| Finasteride | Finasteride | 253 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 231 | 77 |
| Clonazepam | Clonazepam | 231 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 227 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 63 |
| Simvastatin | Simvastatin | 214 | 49 |
| Farxiga | Dapagliflozin Propanediol | 213 | 45 |
| Pregabalin | Pregabalin | 209 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 204 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 195 | 34 |
| Famotidine | Famotidine | 190 | 31 |
| Lorazepam | Lorazepam | 188 | 60 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 185 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 30 |
| Sertraline Hcl | Sertraline Hcl | 170 | 38 |
| Ezetimibe | Ezetimibe | 169 | 39 |
| Xarelto | Rivaroxaban | 169 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 166 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 165 | 37 |
| Metformin Hcl Er | Metformin Hcl | 159 | 48 |
| Ozempic | Semaglutide | 155 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 153 | 31 |
| Atenolol | Atenolol | 148 | 32 |
| Buspirone Hcl | Buspirone Hcl | 146 | 25 |
| Montelukast Sodium | Montelukast Sodium | 145 | 31 |
| Temazepam | Temazepam | 145 | 24 |
| Topiramate | Topiramate | 144 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 142 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 137 | 37 |
| Diazepam | Diazepam | 133 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 131 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 122 | 14 |
| Fenofibrate | Fenofibrate | 122 | 27 |
| Bupropion Xl | Bupropion Hcl | 115 | 17 |
| Alendronate Sodium | Alendronate Sodium | 114 | 26 |
| Mirtazapine | Mirtazapine | 110 | 27 |
| Trulicity | Dulaglutide | 108 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 27 |
| Celecoxib | Celecoxib | 107 | 21 |
| Bumetanide | Bumetanide | 105 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 31 |
| Allopurinol | Allopurinol | 104 | 23 |
| Ondansetron Odt | Ondansetron | 103 | 45 |
| Ropinirole Hcl | Ropinirole Hcl | 99 | 17 |
| Januvia | Sitagliptin Phosphate | 98 | 18 |
| Prednisone | Prednisone | 97 | 52 |
| Amitriptyline Hcl | Amitriptyline Hcl | 96 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 95 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 94 | 23 |
| Repatha Sureclick | Evolocumab | 91 | 14 |
| Glipizide | Glipizide | 90 | 29 |
| Sucralfate | Sucralfate | 90 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 89 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 88 | 13 |
| Levetiracetam | Levetiracetam | 86 | 14 |
| Lovastatin | Lovastatin | 84 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 62 |
| Bupropion Hcl Sr | Bupropion Hcl | 75 | 18 |
| Myrbetriq | Mirabegron | 75 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 73 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 73 | 16 |
| Donepezil Hcl | Donepezil Hcl | 73 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 22 |
| Tresiba Flextouch U-100 | Insulin Degludec | 73 | 14 |
| Buprenorphine | Buprenorphine | 72 | suppressed |
| Azithromycin | Azithromycin | 71 | 62 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 71 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 70 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 14 |
| Metolazone | Metolazone | 66 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 65 | 11 |
| Clonidine Hcl | Clonidine Hcl | 65 | 18 |
| Enalapril Maleate | Enalapril Maleate | 63 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 63 | 11 |
| Meclizine Hcl | Meclizine Hcl | 62 | 19 |
| Mounjaro | Tirzepatide | 62 | 12 |
| Divalproex Sodium | Divalproex Sodium | 61 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 39 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 11 |
| Aripiprazole | Aripiprazole | 58 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | 18 |
| Memantine Hcl | Memantine Hcl | 55 | 16 |
| Olanzapine | Olanzapine | 53 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 51 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 50 | 13 |
| Levemir Flexpen | Insulin Detemir | 49 | 11 |
| Primidone | Primidone | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 36 |
| Venlafaxine Hcl | Venlafaxine Hcl | 45 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 44 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 30 |
| Methadone Hcl | Methadone Hcl | 43 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 43 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 43 | suppressed |
| Methotrexate | Methotrexate Sodium | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Cephalexin | Cephalexin | 41 | 34 |
| Morphine Sulfate | Morphine Sulfate | 41 | 31 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 11 |
| Phenobarbital | Phenobarbital | 40 | suppressed |
| Acyclovir | Acyclovir | 39 | suppressed |
| Linzess | Linaclotide | 39 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 33 |
| Valsartan | Valsartan | 37 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 17 |
| Risperidone | Risperidone | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 31 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Nystatin | Nystatin | 30 | 20 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | suppressed |
| Loperamide | Loperamide Hcl | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 27 | 12 |
| Lidocaine | Lidocaine | 26 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 21 |
| Ketoconazole | Ketoconazole | 25 | 15 |
| Mupirocin | Mupirocin | 25 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 20 |
| Rizatriptan | Rizatriptan Benzoate | 25 | suppressed |
| Cimetidine | Cimetidine | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 23 | 23 |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Acarbose | Acarbose | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Felbamate | Felbamate | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Acetic Acid | Acetic Acid | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Butrans | Buprenorphine | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Prevalite | Cholestyramine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,278.28 · 85 records | Lilly USA, LLC | AREXVY, BREZTRI, Belbuca, CAPLYTA, ENTRESTO, EVENITY, GEMTESA, GVOKE HYPOPEN, INGREZZA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAQEL, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error